Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) plummeted after-hours Monday after four patents on Copaxone were invalidated. The stock fell as much as 10% to nearly $31. Teva Pharmaceuticals has been under pressure for months from government threats of drug price curbs. The stock is trading at 10 year lows. I am alerting investors that there is major support on Teva Pharmaceuticals at $30.00. This is where I expect it to bounce based on historic support stretching back to 2006. I expect a long term bottom in the $30 range and will be accumulating a large position.